

Novartis coronavirus update (supply chain, response measures, EFPIA R&D call) ^[1]

Publish Date: 11 March 2020 12:00 CET

As Novartis continues to closely monitor the coronavirus situation, our primary concern is the health and safety of our associates and patients globally. We will continue to deliver our medicines to patients around the world and we do not anticipate supply chain disruption at this time.

Novartis has also put the following measures in place:

- We are implementing general international travel restrictions
- We have issued guidance on how our associates can protect themselves against coronavirus infection
- We have enacted mitigation plans where needed to protect the integrity of our trials and help ensure continuity of treatment.*

In response to an urgent call for research and development on coronavirus, issued by the [European Federation of Pharmaceutical Industries and Associations \(EFPIA\)](#) ^[2], Novartis has expressed its willingness to contribute to this important effort by making available a set of compounds from our libraries that we consider suitable for in vitro antiviral testing. In addition, we are evaluating our existing products to see if any could be repurposed beyond their approved indications.

Our generics business Sandoz has committed to keeping prices stable for a basket of essential medicines that may help in the treatment of coronavirus cases, specifically antivirals to reduce the impact of coronavirus and antibiotics to combat pneumonia. [Read the Sandoz media release](#) ^[3].

Novartis remains responsive to any developments regarding coronavirus and will take all necessary steps to protect its associates and patients as the situation evolves.

Disclaimer:

* *Updated on April 24, 2020 (clinical trials mitigation plans)*

Source URL: <https://www.novartis.com/news/novartis-coronavirus-update-supply-chain-response-measures-efpia-rd-call>

Links

[1] <https://www.novartis.com/news/novartis-coronavirus-update-supply-chain-response-measures-efpia-rd-call>

[2] <https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/european-pharmaceutical->

industry-response-to-coronavirus/

[3] <https://www.sandoz.com/news/media-releases/sandoz-commits-keep-prices-stable-basket-essential-medicines>